Valuation and View: We introduce CY19 numbers. We have penciled 8% CAGR in revenues over for the next two years. With contribution from high value added products and benefit from operating leverage, we think 14% CAGR in EBITDA, over the next two years, should possible. Yet even after valuing the stock at 15x CY19 EV/EBITDA, we fail to see...